Replies to post #187097 on Biotech Values

[DewDiligence]

PTLA selling $115M* of stock at unspecified price:

http://finance.yahoo.com/news/portola-pharmaceuticals-announces-proposed-offering-201248535.html

*Assuming exercise of underwriter’s option.

[DewDiligence]

PTLA upsized the phase-3 trial of Betrixaban from 6850 to 7500 patients to maintain the desired statistical power. (Source: 2Q15 CC.)